8-K: Candel Therapeutics' CAN-3110 Receives FDA Fast Track Designation for Recurrent High-Grade Glioma Treatment

Candel Therapeutics' CAN-3110, a novel oncolytic viral immunotherapy, has been granted Fast Track Designation by the FDA for the treatment of recurrent high-grade glioma.

Summary

• Candel Therapeutics announced that the FDA has granted Fast Track Designation to CAN-3110, their lead herpes simplex virus (HSV)-based product candidate.
• CAN-3110 is an investigator-sponsored HSV-1 oncolytic viral immunotherapy being developed for the treatment of recurrent high-grade glioma (HGG).
• The Fast Track Designation aims to expedite the development and review of drugs that treat serious conditions and fulfill unmet medical needs.
• A Phase 1b clinical trial of CAN-3110 showed a nearly doubling of the expected median overall survival (mOS) after a single injection, reaching approximately 12 months compared to historical reports of 6 to 9 months.
• Patients with positive HSV-1 serology in the trial experienced a median overall survival of 14 months.
• The trial also showed that CAN-3110 was well tolerated with no dose-limiting toxicity reported.
• The company expects to report additional data from the ongoing phase 1b clinical trial, including the potential benefits from multiple injections of CAN-3110, in the second half of 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the FDA's Fast Track Designation and promising clinical trial results, indicating a potential breakthrough in a difficult-to-treat cancer. The lack of negative information and the focus on future data releases further contribute to the positive outlook.

Positives

• The FDA's Fast Track Designation will help expedite the development and review process for CAN-3110.
• CAN-3110 has shown promising results in a Phase 1b clinical trial, with a significant increase in median overall survival compared to historical data.
• The treatment was well tolerated with no dose-limiting toxicity reported.
• Positive HSV-1 serology was a predictor of response and associated with improved survival.
• The company is exploring the effects of multiple injections of CAN-3110, with initial results expected in the second half of 2024.

Risks

• The development of CAN-3110 is still in the clinical trial phase, and there is no guarantee of regulatory approval.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company is dependent on the success of its clinical trials and the ability to obtain and maintain regulatory approval.
• The company's ability to maintain its intellectual property is also a risk.

Future Outlook

Candel expects to report additional data from the ongoing phase 1b clinical trial, including the potential benefits from multiple injections of CAN-3110, in the second half of 2024. They also plan to initiate IND-enabling work in a second indication characterized by Nestin expression.

Management Comments

• Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel, stated that the Fast Track Designation reinforces the critical need for effective treatment options for patients with recurrent HGG and supports the potential of CAN-3110.
• Antonio Chiocca, MD, PhD, Head of Department of Neurosurgery at Brigham and Womens Hospital, expressed his anticipation for the potential of accelerating the development of CAN-3110 and bringing this therapy to patients.

Industry Context

The announcement highlights the ongoing efforts to develop novel immunotherapies for aggressive cancers like recurrent high-grade glioma, where current treatments have limited efficacy. The Fast Track Designation underscores the FDA's recognition of the unmet medical need and the potential of CAN-3110 to address this.

Comparison to Industry Standards

• The median overall survival of 12 months observed in the CAN-3110 trial is a significant improvement compared to the historical 6-9 months for recurrent high-grade glioma, suggesting a potential breakthrough in this difficult-to-treat condition.
• While specific competitor data is not provided in the document, the focus on oncolytic viral immunotherapy represents a growing area of research in cancer treatment, with companies like BioNTech and Amgen also exploring similar approaches.
• The use of HSV-1 as a vector for oncolytic therapy is a unique approach, differentiating Candel from companies using other viral vectors or traditional chemotherapy methods.
• The observed 14-month median overall survival in HSV-1 positive patients is particularly noteworthy, indicating a potential biomarker for treatment response.

Stakeholder Impact

• Shareholders may view the Fast Track Designation and positive clinical trial results as a positive development.
• Patients with recurrent high-grade glioma and their families may have increased hope for a new treatment option.
• Employees of Candel Therapeutics may be motivated by the progress of CAN-3110.
• The medical community may be interested in the potential of CAN-3110 as a new treatment approach.

Next Steps

• Candel expects to report additional data from the ongoing phase 1b clinical trial in the second half of 2024.
• The company plans to initiate IND-enabling work in a second indication characterized by Nestin expression.

Key Dates

Keywords

CAN-3110, Fast Track Designation, FDA, Recurrent High-Grade Glioma, Oncolytic Viral Immunotherapy, HSV-1, Immunotherapy, Cancer Treatment, Clinical Trial, Median Overall Survival